Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06206941 · ClinicalTrials.gov registry record
IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer
A clinical trial of Cancer, sponsored by State University of New York at Buffalo.
- Recruiting
- Registry status
- 450
- Enrollment target
- 2
- Study locations
NCT06206941 is a study of Cancer that is actively recruiting participants, run by State University of New York at Buffalo. The registered enrollment target is 450 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06206941, a study of Cancer, is actively recruiting participants, sponsored by State University of New York at Buffalo.
- RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research is to assess how patients with cancer being treated with Immune Checkpoint Inhibitors (ICI) manage symptoms related to cancer and/or its treatment. Patients use a variety of ways to manage symptoms including traditional and alternative treatments including cannabis, acupuncture, etc. This research will have an important impact on our knowledge of cancer symptom management, and ultimately improve patient care and safety. Participants will complete online surveys and 7 days of ecological momentary assessments at 0, 1, 2, 4, 6, 9 and 12 month to compare the cannabis users and non cannabis users symptoms.
Conditions Studied
Study Locations (2)
Oregon
- Oregon Health and Science University - Portland
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2025-01-02 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06206941
The ClinicalTrials.gov registry entry for NCT06206941 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (87% lower). The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06206941 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Oregon, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06206941 about?
NCT06206941 is a clinical study titled "IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer". The purpose of this research is to assess how patients with cancer being treated with Immune Checkpoint Inhibitors (ICI) manage symptoms related to cancer and/or its treatment. Patients use a variety of ways to manage symptoms including traditional and alternative treatments including cannabis, acup...
What is the current status of trial NCT06206941?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2025-01-02. Estimated completion is 2027-12-31.
What conditions does trial NCT06206941 study?
This clinical trial studies the following conditions: Cancer.
Who is sponsoring clinical trial NCT06206941?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06206941 being conducted?
This trial has 2 study locations across Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.